Evidence map›Paper›PMID 33591944›Full record

ArticleAging2021

Identification of novel candidate biomarkers for pancreatic adenocarcinoma based on TCGA cohort.

Yang Jie, Wang Peng, Yuan-Yuan Li

Open access · greenAbstract readValidation Study
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Yang JieDepartment of Pharmacy, Shandong Provincial Hospital, Jinan 250022, Shandong, P.R. China.
Wang PengDepartment of Pharmacy, The First Affiliated Hospital of Shandong First Medical University, Jinan 250014, Shandong, P.R. China.
Yuan-Yuan LiDepartment of Pharmacy, The First Affiliated Hospital of Shandong First Medical University, Jinan 250014, Shandong, P.R. China.
Shandong First Medical University · CNShandong Provincial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic adenocarcinoma (PAAD) is the most serious solid tumor type throughout the world. The present study aimed to identify novel biomarkers and potential efficacious small drugs in PAAD using integrated bioinformatics analyses. A total of 4777 differentially expressed genes (DEGs) were filtered, 2536 upregulated DEGs and 2241 downregulated DEGs. Weighted gene co-expression network analysis was then used and identified 12 modules, of which, blue module with the most significant enrichment result was selected. KEGG and GO enrichment analyses showed that all DEGs of blue module were enriched in EMT and PI3K/Akt pathway. Three hub genes (

Indexed as

AdenocarcinomaBiomarkers, TumorCase-Control StudiesCell Line, TumorDrug Screening Assays, AntitumorGene Regulatory NetworksHumansIntegrin beta1Integrin beta ChainsMicroRNAsPancreatic NeoplasmsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktThapsigarginBiomarkers, TumorIntegrin beta1Integrin beta ChainsItgb1 protein, humanITGB5 protein, humanMicroRNAsMIRN16 microRNA, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktThapsigarginbiomarkerconnectivity map (CMap)pancreatic adenocarcinoma (PAAD)small molecule drugweighted co-expression network analysis (WGCNA)

Identifiers

PMID33591944
PMCPMC7950294
OpenAlexW3133156153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.